Syndax Readies FDA Filing In Leukemia After Stopping Revumenib Trial Early For Efficacy
The AUGMENT-101 study showed a strong response rate among acute leukemia patients who historically have a poor prognosis.
The AUGMENT-101 study showed a strong response rate among acute leukemia patients who historically have a poor prognosis.